Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 14 2019 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
SEC
File Number 333-191725
NOTIFICATION
OF LATE FILING
(Check
One)
:
☐
Form
10-K
☐
Form
20-F
☐
Form
11-K
☒
Form
10-Q
☐
Form
10-D
☐
Form
N-SAR
☐
Form
N-CSR
For
Period Ended: March 31, 2019
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
For
the Transition Period Ended: ________________________
Nothing in this form shall
be construed to imply that the Commission has verified any information contained herein.
If the notification relates
to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART I -- REGISTRANT INFORMATION
Regen
Biopharma, Inc.
|
|
Full Name of Registrant
|
|
|
|
|
|
Former Name of Registrant
|
|
|
|
4700
Spring Street, Suite 304
|
|
Address of Principal
Executive Officer (Street and Number)
|
|
|
|
La
Mesa, CA 91942
|
|
City, State and Zip
Code
|
|
PART II -- RULES 12b-25(b)
AND (c)
If the subject report could
not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate.)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or
Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form
10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date;
and
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III-- NARRATIVE
State
below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period. (Attach extra sheets if needed.)
The
Company could not complete the filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2019 due
to a delay related to the review being performed by the Company’s public accountant which delay could not be eliminated
by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934,
as amended, the Company will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.
PART
IV -- OTHER INFORMATION
(1) Name and telephone number
of person to contact in regard to this notification
David
Koos
|
|
(619)
|
|
702-1404
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒
Yes
☐
No
(3) Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will
be reflected by the earnings statements to be included in the subject report or portion thereof?
☐
Yes
☒
No
If so:
attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Regen Biopharma, Inc.
(Name
of Registrant as Specified in Charter)
Has caused this notification
to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
May 13, 2019
|
By:
|
/s/
David Koos
|
|
|
David Koos
|
|
|
Chief Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Apr 2023 to Apr 2024